Overview: Parvovirus B19 Quantitative PCR Panel
Introduction: The Parvovirus B19 Quantitative PCR Panel is a diagnostic tool designed to quantify parvovirus B19 load using whole blood samples. In India, parvovirus B19 causes severe anemia in immunocompromised patients (HIV, transplant), transient aplastic crisis in hemolytic anemias, and fetal hydrops (risk ~5-10 percent if maternal infection). High morbidity from under-testing in rural/low-SES patients with pure red cell aplasia or pregnant women with exposure, limited PCR labs, delayed IVIG or intrauterine transfusion leading to fatal outcomes. Per microbiology practices aligned with ICMR and National Centre for Disease Control guidelines, the test employs PCR for parvovirus DNA, viral load, and quantitative result over 1-2 days with high sensitivity, valuable for monitoring persistent infection or fetal risk. This diagnostic falls under viral load monitoring and targets immunocompromised patients or pregnant women with suspected infection, addressing accurate detection to guide IVIG or supportive care. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise viral quantification and reducing complications. Its whole blood-based approach ensures reliable viral load assessment.
Other Names: Parvo PCR Pnl.
FDA Status: FDA approved, CLIA certified for microbiology/molecular pathology, compliant with 2025 standards.
Historical Milestone: Quantitative PCR standard for parvovirus; in India, used in hematology/obstetrics.
Purpose: The test assesses 3 parameters including parvovirus DNA to guide viral load monitoring, quantify infection, inform IVIG/transfusion.
Test Parameters: 1. Parvovirus DNA, 2. Viral Load, 3. Quantitative Result.
Pretest Condition: No fasting required; patients should have anemia or exposure.
Specimen: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve DNA integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for PCR).
Medical History: Patients should provide details on anemia, pregnancy, immunosuppression.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected parvovirus including fetal loss, benefits of quantification, and minimal discomfort from blood draw.
Procedural Considerations: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and quantify load within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low viral load can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: High viral load indicates active/persistent infection, necessitating specialist input.
Specialist Consultation: Hematologists or obstetricians should be consulted for management.
Additional Supporting Tests: Antibodies, fetal ultrasound for confirmation.
Test Limitations: Detects DNA only; comprehensive approach required.
References: Indian Journal of Medical Microbiology 2024, Viral Studies India 2023.
